Invokana®

What is Invokana®?

Invokana® (canagliflozin) is a prescription drug approved by the FDA in 2013 to help people with type-2 diabetes control their blood-sugar levels. It is manufactured by Johnson & Johnson’s Janssen Pharmaceuticals unit. Other similar drugs (called “SGLT2 Inhibitors”)  on the market include:

  • Invokamet
  • Farxiga
  • Jardiance
  • Glyxambi
  • Xigduo XR

How Does Invokana® Work?

Invokana® may prevent hyperglycemia (high blood-sugar levels) by helping the patient’s kidneys remove excess sugar from the body through the urine.

Why is this a problem?

Invokana® has also been linked to hundreds of severe adverse events including Diabetic Ketoacidosis and kidney failure.

In May 2015, the FDA issued a Safety Communication for Invokana® and all other drugs in the SGLT2 inhibitor class, after receiving reports of patients who developed Diabetic Ketoacidosis. This is a serious medical condition that results from high glucose (blood sugar) levels. It causes blood pH levels to drop precipitously, acidifying the blood. Without emergency medical intervention, ketoacidosis can lead to kidney failure, coma and death. Ketoacidosis can appear suddenly and unexpectedly – and therefore, may not be diagnosed right away.

The FDA continues to receive more reports of this side effect and warns people to: “Pay close attention for any signs or symptoms of acidosis such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness. Seek medical attention immediately if you experience any of these symptoms.”

Protect your rights. Get compensated for your injuries.

If you or a loved one has suffered serious complications such as diabetic ketoacidosis or kidney failure after taking Invokana® or one of the other drugs in the SGLT2 inhibitor class, you may be entitled to compensation. Complete the Quick Intake form at the top of this page or call our legal intake center at 1 (800) 438-6453 to receive your FREE case evaluation.